SCTX (Scribe Therapeutics) EV-to-EBITDA: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $30.01
! 1 Warning Sign
View Full Analysis

What is Scribe Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scribe Therapeutics's enterprise value is $568.40 Mil. Scribe Therapeutics does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Scribe Therapeutics's EV-to-EBITDA at this moment.

The historical rank and industry rank for Scribe Therapeutics's EV-to-EBITDA or its related term are showing as below:

SCTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.8   Med: 0   Max: 0
Current: -31.33
SCTX's EV-to-EBITDA is ranked worse than
100% of 403 companies
in the Biotechnology industry
Industry Median: 13.21 vs SCTX: -31.33

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-09-11), Scribe Therapeutics's stock price is $30.01. Scribe Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Scribe Therapeutics's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Scribe Therapeutics  (NAS:SCTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Scribe Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.01/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Scribe Therapeutics EV-to-EBITDA Related Terms

Scribe Therapeutics EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics EV-to-EBITDA Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Scribe Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

SCTX vs ARTV, CABA, OVID: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Scribe Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's EV-to-EBITDA falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics EV-to-EBITDA Calculation

Scribe Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=568.401/
=

Scribe Therapeutics Business Description

Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.01
Price